Generally, cancer arises from cumulative genetic and/or epigenetic alterations, and the genetic changes in key signaling pathways have been reported so far, including PI3K/Akt/mTOR, TP53, and WNT/beta-catenin signaling, but its clinical application is still limited [10]. This evidence concerns the gene TP53 and cancer.